Amylyx Pharmaceuticals, Inc.
NASDAQ Global SelectCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.Company Description
- CEO
- Joshua Cohen
- Full Time Employees
- 136
- Sector
- Healthcare
- Industry
- Biotechnology
- Address
- 55 Cambridge Parkway Cambridge MA United States of America 02142
- IPO Date
- Jan 7, 2022
- CIK
- 0001658551
- Website
- amylyx.com
- Similar Companies
- Business
- Amylyx Pharmaceuticals, Inc. Amylyx Pharmaceuticals, Inc. (Nasdaq: AMLX) is a clinical-stage biopharmaceutical company that discovers, develops and seeks to commercialize novel therapies addressing high unmet needs in neurodegenerative and endocrine diseases. Founded in 2013 and headquartered at 43 Thorndike Street in Cambridge, Massachusetts, the company advances a pipeline of investigational therapies including its lead candidate avexitide, a first-in-class glucagon-like peptide-1 (GLP-1) receptor antagonist for post-bariatric hypoglycemia (PBH) and congenital hyperinsulinism (HI), both of which carry FDA Breakthrough Therapy and Orphan Drug Designations; AMX0035, an oral fixed-dose combination of sodium phenylbutyrate and taurursodiol targeting endoplasmic reticulum stress and mitochondrial dysfunction for Wolfram syndrome and progressive supranuclear palsy (PSP); and AMX0114, an antisense oligonucleotide inhibiting calpain-2 for amyotrophic lateral sclerosis (ALS), which holds FDA Fast Track Designation. Amylyx operates globally through subsidiaries such as Amylyx Pharmaceuticals Canada Inc. in Calgary, Amylyx Pharmaceuticals Japan K.K., and Amylyx Pharmaceuticals EMEA B.V. in Amsterdam, targeting patient communities in the United States, Canada, Europe and Japan. Recent developments include the July 2024 acquisition of avexitide from Eiger BioPharmaceuticals for $35.1 million plus assumed liabilities and royalties, initiation of the Phase 3 LUCIDITY trial in PBH with first patient dosed in April 2025 and recruitment completion expected in Q1 2026 yielding topline data in Q3 2026, positive Week 48 data from the Phase 2 HELIOS trial of AMX0035 in Wolfram syndrome in May 2025 supporting a planned pivotal Phase 3 start in H2 2026 pending FDA alignment, full enrollment of Phase 1 LUMINA cohort 1 for AMX0114 in ALS in September 2025 with early data presentation at the December 2025 International Symposium on ALS/MND, a December 2024 collaboration with Gubra A/S to develop a novel long-acting GLP-1 receptor antagonist advancing toward a potential development candidate decision soon, and a September 2025 public offering raising approximately $191 million to extend cash runway into 2028 through avexitide's potential 2027 launch if approved.
Company News
Is GLP-1 Stock Amylyx Still a Buy After Skyrocketing 247%?
BlackRock Inc. Acquires New Stake in Amylyx Pharmaceuticals, Inc. $AMLX
BlackRock Inc. Acquires New Stake in Amylyx Pharmaceuticals, Inc. $AMLX
20 stocks likely to lose money even if the bull market continues
Almitas Capital LLC Buys Shares of 974,881 Amylyx Pharmaceuticals, Inc. $AMLX
Deutsche Bank AG Takes Position in Amylyx Pharmaceuticals, Inc. $AMLX
Why Amylyx Pharmaceuticals Blasted Nearly 79% Higher This Week
Amylyx Pharmaceuticals Announces Pricing of an Upsized $500 Million Underwritten Public Offering of Common Stock
Amylyx Pharmaceuticals Announces Pricing of an Upsized $500 Million Underwritten Public Offering of Common Stock
AMLX Rises as Avexitide Nears 2026-End Filing With Phase III Study Win
Why Amylyx Pharmaceuticals Stock Skyrocketed Today
Amylyx Pharmaceuticals Announces $350.0 Million Proposed Public Offering of Common Stock
Amylyx stock soars on GLP-1 success: here's why investors should sell
Amylyx Pharmaceuticals, Inc. (AMLX) Discusses Positive Phase III LUCIDITY Topline Results for Avexitide in Post-Bariatric Hypoglycemia Transcript
Amylyx: Upgraded To Strong Buy On LUCIDITY Outcome, Avexitide, And 2026 Catalysts
Amylyx Phase III Avexitide Trial Cuts Severe Hypoglycemic Events 55%
Amylyx Pharmaceuticals Comes Closer to Potentially Delivering First Treatment for Weight Loss Surgery-Related Low Suger Level
Amylyx Stock Surges 21% After GLP-1 Drug Succeeds in Phase 3 Trial
Amylyx drug cuts low blood sugar episodes in bariatric surgery patients in key trial
Amylyx Pharmaceuticals Announces Positive Topline Results from Phase 3 LUCIDITY Clinical Trial of Avexitide in Post-Bariatric Hypoglycemia